Greenleaf Trust lifted its holdings in shares of AstraZeneca plc (NYSE:AZN) by 73.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,164 shares of the company’s stock after purchasing an additional 6,440 shares during the period. Greenleaf Trust’s holdings in AstraZeneca were worth $526,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the company. Fisher Asset Management LLC increased its stake in shares of AstraZeneca by 2.7% during the 4th quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock worth $413,531,000 after purchasing an additional 315,759 shares in the last quarter. Wells Fargo & Company MN boosted its position in AstraZeneca by 7.6% during the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock worth $149,303,000 after acquiring an additional 310,389 shares during the last quarter. Ameriprise Financial Inc. boosted its position in AstraZeneca by 7.1% during the third quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock worth $102,643,000 after acquiring an additional 199,519 shares during the last quarter. Capital Bank & Trust Co boosted its position in AstraZeneca by 2.1% during the third quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock worth $92,499,000 after acquiring an additional 57,353 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in AstraZeneca by 18.3% during the third quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock worth $86,695,000 after acquiring an additional 395,699 shares during the last quarter. 14.75% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently issued reports on AZN shares. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, January 10th. Leerink Swann raised their target price on shares of AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Sanford C. Bernstein raised their target price on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, JPMorgan Chase & Co. upgraded shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research report on Friday, December 29th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $35.20.
AstraZeneca plc (NYSE AZN) opened at $34.02 on Friday. The firm has a market cap of $87,229.29, a price-to-earnings ratio of 14.35, a price-to-earnings-growth ratio of 2.08 and a beta of 0.70. AstraZeneca plc has a 1-year low of $28.43 and a 1-year high of $36.70. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.93.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.86. The company had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. AstraZeneca’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter last year, the business earned $1.21 EPS. equities research analysts expect that AstraZeneca plc will post 1.67 earnings per share for the current year.
The business also recently declared a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be issued a $0.95 dividend. The ex-dividend date is Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio (DPR) is presently 57.81%.
COPYRIGHT VIOLATION WARNING: This piece was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2018/02/16/greenleaf-trust-acquires-6440-shares-of-astrazeneca-plc-azn.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.